Stocks
Alcon’s Brytly Eye Drops Secure Over-the-Counter Approval
Alcon has announced the over-the-counter approval of its Brytly eye drops, marking a strategic expansion in its product portfolio and market reach.
#stocks 141 articles
Stocks
Newmont (NEM) Shares Cross Below Key 200-Day Moving Average
Newmont Corp (NEM) shares dropped below their 200-day moving average of $112.00 on Wednesday, trading as low as $109.83. The stock was...
Stocks
THM Shares Hit $1.98, Enter Oversold Territory by RSI
Shares of International Tower Hill Mines Ltd (THM) dipped to $1.98 on Wednesday, entering oversold territory as defined by the Relative Strength...
Stocks
Kimco Realty Class M Preferred Shares Yield Over 7%
Kimco Realty Corp's 5.25% Class M Preferred Stock (KIM.PRM) saw its yield surpass the 7% threshold on Wednesday. This occurred as shares...
Stocks
S&P 500 Firms Beat EPS Estimates, Show Growth
Nine out of ten key S&P 500 companies reporting this week surpassed EPS expectations and demonstrated year-over-year growth, signaling corporate resilience.
Stocks
Sidus Sets Early 2027 Fortis VPX Launch, Secures $158.5M
Sidus Space targets early 2027 for Fortis VPX commercial availability, backed by $158.5 million in Q2 capital raises. CEO Carol Craig noted...
Stocks
AmpliTech Shifts 2026 Focus as Revenue Guidance Uncertain
AmpliTech Group is prioritizing 2026 strategic goals but has withdrawn its $50 million full-year revenue forecast due to deployment timing changes.
Stocks
Spero Secures Cash Runway to H2 2029 with $105M Financing
Spero Therapeutics has extended its cash runway into the second half of 2029 following a $105 million nondilutive royalty financing. This move,...
Stocks
SES AI Reaffirms 2026 Revenue Target, Eyes 1M Cells Annually
SES AI reaffirms its 2026 revenue guidance of $30M-$35M and aims to produce 1 million NDAA-compliant cells per year starting Q4.